Programmable RNA demethylation re-sensitizes bladder cancer to cisplatin

Cisplatin-based chemotherapy remains a cornerstone of treatment for advanced bladder cancer, yet resistance to this platinum drug severely limits its clinical benefit. A new study published in Cellular and Molecular Life Sciences traces one route to that resistance back to a chemical tag on RNA, and then shows that the tag can be surgically removed with a programmable RNA-editing tool. The result is a proof-of-concept strategy in which targeted RNA demethylation of a single messenger RNA restores a form of cell death called ferroptosis and re-sensitizes bladder tumors to cisplatin, both in cell culture and in mouse xenograft models.

The chemical tag in question is 5-methylcytosine, or m5C, a modification deposited on RNA molecules by cellular methyltransferases. Like DNA methylation, RNA methylation is reversible, and the study focused on TET2, an enzyme better known for its role in DNA demethylation that can also act on RNA. Working from public datasets, clinical bladder cancer specimens, and laboratory models of cisplatin-resistant bladder cancer cells, the research team found that TET2 expression was reduced in resistant cells. That loss of TET2 correlated with increased m5C enrichment on the messenger RNA encoding NFE2L2, the gene that produces NRF2, a master transcription factor controlling cellular antioxidant defenses.

NRF2 sits at the center of the cell’s response to oxidative stress. When active, it switches on a battery of genes that help the cell neutralize reactive oxygen species, including SLC7A11, which encodes a subunit of the cystine/glutamate antiporter responsible for importing cystine, the raw material cells need to build the antioxidant glutathione. The researchers found that NFE2L2 messenger RNA and NRF2 protein were both upregulated in bladder cancer tissues and in cisplatin-resistant cells, and that this upregulation was associated with poor prognosis. Mechanistically, m5C marks on the NFE2L2 transcript recruited YBX1, an RNA-binding protein, which stabilized the messenger RNA and prolonged its lifetime, keeping NRF2 levels high.

High NRF2 activity, the study shows, is what allows resistant bladder cancer cells to dodge cisplatin. Cisplatin kills cells partly by generating oxidative stress, and cells with robust antioxidant capacity are better equipped to survive that assault. The team demonstrated that NRF2 binds directly to the SLC7A11 promoter region using chromatin immunoprecipitation followed by quantitative PCR, and that wild-type SLC7A11 promoter reporters were activated by NRF2 while mutant versions were not, confirming a sequence-dependent activation. This NRF2-SLC7A11 axis suppresses lipid peroxidation, the biochemical hallmark of ferroptosis, an iron-dependent form of regulated cell death driven by oxidative damage to cellular membranes.

Ferroptosis suppression has previously been implicated in chemotherapy resistance, but the upstream epitranscriptomic mechanisms remained unclear. The new work fills that gap by identifying a regulatory axis running from TET2 through m5C modification, YBX1-dependent transcript stabilization, NRF2 activation, and SLC7A11 upregulation, ultimately shielding bladder cancer cells from both ferroptosis and cisplatin-induced death. When TET2 is scarce, m5C marks accumulate on NFE2L2 messenger RNA, YBX1 stabilizes the transcript, NRF2 rises, SLC7A11 follows, glutathione is plentiful, and the cell becomes nearly impervious to platinum-based killing.

To reverse this cascade, the researchers deployed a programmable RNA demethylation system combining dCas13b, a catalytically inactive RNA-targeting protein derived from bacterial CRISPR machinery, with TET2, the demethylase enzyme. dCas13b can be guided by a custom RNA sequence to bind almost any target transcript with high specificity, and fusing it to TET2 converts it into a site-directed eraser of m5C marks. In this study, the dCas13b-TET2 construct was programmed to target the NFE2L2 messenger RNA directly, stripping m5C modifications from that specific transcript without broadly altering the RNA methylome.

The consequences were striking. Targeted demethylation of NFE2L2 messenger RNA reduced m5C enrichment on the transcript, accelerated its decay, and lowered NRF2 protein expression. With NRF2 no longer propping up the antioxidant program, lipid peroxidation increased, glutathione stores were depleted, and cisplatin sensitivity rose markedly in resistant bladder cancer cells. The team also showed that restoring SLC7A11 partially reversed these effects, confirming that the SLC7A11 arm of the pathway is functionally downstream of the demethylation intervention and that the ferroptosis sensitization depends on disrupting this specific NRF2 target.

In vivo, the approach translated into improved cisplatin efficacy in xenograft models of bladder cancer. Mice receiving the targeted demethylation system alongside cisplatin showed enhanced tumor control compared with cisplatin alone. Importantly, under the conditions tested, the researchers detected no changes in body weight and no overt organ histopathology, suggesting that the intervention was well tolerated in the experimental setting. TET2-RIP recovery controls confirmed that comparable amounts of immunoprecipitated TET2 protein were recovered from parental and resistant cells, supporting the interpretation that the difference in m5C burden reflects altered TET2 activity or availability rather than technical artifacts of the immunoprecipitation procedure.

The study’s technical toolkit is worth noting for what it reveals about how the mechanism was pinned down. Beyond m5C-RIP and RNA immunoprecipitation, the researchers used RNA pull-down assays to confirm physical interactions between the modified transcript and YBX1, Actinomycin D chase assays to measure transcript half-life, and promoter and RNA reporter constructs to test NRF2-dependent transcription in a controlled system. Together, these experiments build a coherent causal chain from a single RNA modification to a clinically relevant drug response, rather than merely correlating m5C levels with resistance.

What makes this work especially compelling is the precision of the therapeutic concept. Rather than globally inhibiting methyltransferases or demethylases, which would alter thousands of transcripts at once and risk widespread toxicity, the dCas13b-TET2 system edits a single messenger RNA target. This level of specificity opens a path toward RNA epigenetic therapy in bladder cancer, where the disease-driving modification can be removed without disturbing the rest of the transcriptome. The authors frame their findings as a proof of concept, and the approach will need further development in delivery, safety, and scalability before clinical translation. Nonetheless, the identification of a TET2-m5C-YBX1-NRF2-SLC7A11 axis as a driver of cisplatin resistance, and the demonstration that targeted RNA demethylation can break that axis and restore ferroptosis, marks a significant advance in understanding how bladder cancer outmaneuvers chemotherapy and how that evasion might be undone.

Subject of Research: Targeted RNA m5C demethylation restores ferroptosis and overcomes cisplatin resistance in bladder cancer

Article Title: Targeted RNA m5C demethylation of NFE2L2 mRNA by dCas13b-TET2 restores ferroptosis and overcomes cisplatin resistance in bladder cancer

Article References: Zhao, Z., Li, A., Wu, Y., Huang, Y., Ma, W., Li, M., Huang, X., Ding, M., Cao, C., & Li, S. (2026). Targeted RNA m5C demethylation of NFE2L2 mRNA by dCas13b-TET2 restores ferroptosis and overcomes cisplatin resistance in bladder cancer. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06477-7

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06477-7

Keywords: Targeted, demethylation, NFE2L2, mRNA, dCas13b-TET2, restores, ferroptosis, overcomes, cisplatin, resistance, bladder, cancer